US Broker Ratings

Day One Biopharmaceuticals, Inc (DAWN) Stock Analysis: A Biotech with 219.50% Potential Upside Awaits Investors

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) is a dynamic player in the biotechnology sector, focusing on developing innovative treatments for both childhood and adult diseases. With a market capitalization of..

STAAR Surgical Company (STAA) Valuation Insights: Navigating a High Forward P/E and Mixed Analyst Sentiment

Investors eyeing STAAR Surgical Company (NASDAQ: STAA), a prominent player in the healthcare sector specializing in medical instruments and supplies, will find a mixed bag of metrics and sentiment that..

Cogent Biosciences, Inc. (COGT) Stock Analysis: Promising Upside in Biotech Precision Therapies

Cogent Biosciences, Inc. (NASDAQ: COGT), a biotechnology firm focused on precision therapies for genetically defined diseases, is garnering attention in the healthcare sector with its innovative product pipeline. Headquartered in..

Niagen Bioscience, Inc. (NAGE) Stock Analysis: Exploring a Potential 63% Upside in the Healthcare Sector

Niagen Bioscience, Inc. (NASDAQ: NAGE), a key player in the biotechnology industry, is generating buzz among investors with its impressive growth metrics and promising analyst outlook. Headquartered in Los Angeles,..

Oculis Holding AG (OCS) Stock Report: Analyst Ratings Indicate 129% Potential Upside

Oculis Holding AG (OCS), a promising player in the biotechnology sector, is capturing attention with its innovative approach to treating ophthalmic diseases. Based in Zug, Switzerland, Oculis is a clinical-stage..

Maravai LifeSciences Holdings (MRVI) Stock Analysis: Navigating a Potential 73.32% Upside in the Biotechnology Sector

Maravai LifeSciences Holdings, Inc. (MRVI), a key player in the biotechnology industry, has captured investor attention with a staggering potential upside of 73.32%. Headquartered in San Diego, California, Maravai operates..

Akso Health Group (AHG) Stock Analysis: Exploring a 415.8% Revenue Growth Phenomenon

Akso Health Group (AHG) has recently caught the attention of investors with its remarkable revenue growth of 415.8%, a figure that stands out in the healthcare sector. Operating within the..

Arbutus Biopharma (ABUS) Stock Analysis: Exploring a 43% Potential Upside with Breakthrough Therapies

Arbutus Biopharma Corporation (NASDAQ: ABUS), a clinical-stage biopharmaceutical company, is making waves in the biotechnology sector with its innovative approach to treating infectious diseases. Specializing in developing therapeutics for chronic..

Praxis Precision Medicines, Inc (PRAX) Stock Analysis: Examining a Potential 116% Upside in the Biotech Sector

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) stands at the forefront of the biotechnology sector, developing innovative therapies aimed at treating central nervous system (CNS) disorders. With a market cap of..

Intellia Therapeutics (NTLA) Stock Analysis: Unveiling a 197% Upside Potential in Biotech

Intellia Therapeutics, Inc. (NTLA) is capturing investor attention with its promising advancements in gene editing and an intriguing potential upside. With a market cap of $1.25 billion, this biotechnology company..

AbCellera Biologics Inc. (ABCL) Stock Analysis: Exploring the 115.95% Potential Upside

AbCellera Biologics Inc. (NASDAQ: ABCL), a key player in the biotechnology sector, has been capturing investor attention with its innovative approach to antibody-based medicines. Focusing on unmet medical needs, AbCellera..

Weave Communications, Inc. (WEAV) Stock Analysis: Exploring a 58.83% Upside Potential

Weave Communications, Inc. (NYSE: WEAV) is making waves in the healthcare sector with its innovative approach to customer experience and payment solutions for small to medium-sized businesses. Based in Lehi,..

Simulations Plus, Inc. (SLP)

⚠️ No article content returned.

..

Immunome, Inc. (IMNM): Analyst Consensus and Growth Potential Signal a 137.93% Upside for Investors

Immunome, Inc. (NASDAQ: IMNM), a promising player in the biotechnology sector, is attracting attention due to its notable potential upside of 137.93%, as suggested by analyst ratings. As a clinical-stage..

Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Potential Upside of 129% Draws Investor Attention

Gyre Therapeutics, Inc. (NASDAQ: GYRE) is making waves in the biotechnology sector with its promising pipeline of anti-inflammatory and anti-fibrotic drugs. Headquartered in San Diego, California, and operating as a..

Spyre Therapeutics, Inc. (SYRE) Stock Analysis: Exploring a Potential 222% Upside in Biotechnology

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology firm, is making waves in the healthcare sector with its promising therapeutic developments for inflammatory bowel disease (IBD). As the company focuses..

InMode Ltd. (INMD) Stock Analysis: Unveiling a 25.91% Return on Equity and a Promising 8.91% Upside

InMode Ltd. (NASDAQ: INMD) continues to capture the attention of investors with its innovative approach in the healthcare sector, specifically within the medical devices industry. Headquartered in Yokne’am, Israel, InMode..

Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Exploring a 136% Potential Upside in Healthcare Innovation

Akebia Therapeutics, Inc. (NASDAQ: AKBA) has been capturing the attention of investors with its promising trajectory in the biopharmaceutical sector, specifically targeting kidney diseases. As a company immersed in the..

Ardelyx, Inc. (ARDX) Stock Analysis: Unveiling a 75% Upside Potential in the Biotech Arena

For investors navigating the turbulent waters of the biotechnology sector, Ardelyx, Inc. (NASDAQ: ARDX) stands out as a promising candidate. Positioned in the healthcare sector, Ardelyx is making waves with..

LENZ Therapeutics, Inc. (LENZ) Stock Analysis: Exploring a 33.18% Upside in the Biotech Sector

For investors with a keen eye on the biotechnology sector, LENZ Therapeutics, Inc. (NASDAQ: LENZ) presents a compelling opportunity. The company, which specializes in developing therapies to improve vision, is..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds